C OSBORNE to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications C OSBORNE has written about Clinical Trials, Phase III as Topic.
Connection Strength
0.049
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
Score: 0.020
-
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62.
Score: 0.019
-
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15; 89(4):817-25.
Score: 0.010